The impact of trisomy 12, retinoblastoma gene and P53 in prognosis of B-cell chronic lymphocytic leukemia

Abdelsalam, Mahmoud; Sissy, A. El; Samra, Mohamed; Ibrahim, S.; Markaby, D. El; GadAllah, Farida H.

doi:10.1179/102453308x316121

Cited by 6 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12–13 The frequency of trisomy 12 positive patients in the EFC6663 study is in line this (8 of the 62 (13%)). Although small in number, all eight of the patients on study experienced clinical benefit (7 PR, 1 SD) and whether this extends to a larger patient population needs to be explored.…”

supporting

confidence: 74%

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response

et al. 2014

View full text Add to dashboard Cite

supporting

confidence: 74%

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response

et al. 2014

View full text Add to dashboard Cite

“…The Chromosome 12 is considered as a marker of poor prognosis in B-CLL patients [ 16 ], but it was never correlated with myeloma development. Elnenaei and collaborators [ 17 ] reported this cytogenetic alteration in 8% of their myeloma patients, but with no informative data about previous hematological disorder, such as B-CLL.…”

Section: Discussionmentioning

confidence: 99%

Development of plasma cell myeloma in a B-cell chronic lymphocytic leukemia patient with chromosome 12 trisomy

et al. 2013

View full text Add to dashboard Cite

BackgroundCancer development results from the progressive accumulation of genomic abnormalities that culminate in the neoplastic phenotype. Cytogenetic alterations, mutations and rearrangements may be considered as molecular legacy which trace the clonal history of the disease. Concomitant tumors are reported and they may derive from a common or divergent founder clone. B-cell chronic lymphocytic leukemia (B-CLL) and plasma cell myeloma (PCM) are both mature B-cell neoplasms, and their concomitancy, albeit rare, is documented.Case presentationHere, we described a patient with prior B-CLL with secondary development of PCM. Cytogenetic and multi parametric flow cytometry analyses were performed. The B-CLL population presented chromosome 12 trisomy, unlikely the arisen PCM population.ConclusionThe close follow up of B-CLL patients is important for early intervention in case of development of other malignancy, such as myeloma. Our observation suggests these two diseases may have arisen from different clones. We understand that the investigation of clonal origin may provide important information regarding therapeutic decisions, and should be considered in concomitant neoplasm.

show abstract

“…Conversely, CLL patients with deletions of chromosomes 11 or 17 typically show an aggressive disease, with high risk of relapse, drug resistance development, and a median overall survival of 79 and 32 mo, respectively ( 3 ). Finally, T12 CLLs show atypical morphological/immunophenotypic features and the most variable prognosis ( 11 ), with an overall survival spanning between 9.5 and 15.6 y ( 3 , 12 ). It was previously shown that NOTCH1 mutations are prevalent in T12 CLL and are associated with unfavorable prognosis ( 13 , 14 ).…”

mentioning

confidence: 99%

A large fraction of trisomy 12, 17p ⁻ , and 11q ⁻ CLL cases carry unidentified microdeletions of miR-15a/16-1

Pepe

Rassenti

Pekarsky

et al. 2022

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and is characterized by chromosomal aberrations including 13q, 11q, and 17p deletions and a trisomy of chromosome 12 (T12). 13q deletions are often associated with 11q and 17p deletions in aggressive cases. Conversely, T12 CLLs show a variable prognosis, and association with 13q deletions is uncommon. The miR-15a/16-1 cluster is the functional target of 13q deletions, leading to BCL2 overexpression. Chromosomal aberrations in CLL are associated with prognosis, and their identification is carried out by fluorescence in situ hybridization (FISH). Since standard FISH only detects large deletions, we investigated the presence of undetected microdeletions targeting miR-15a/16-1 in CLL cases. We found that ∼34% of CLL samples show an unreported loss of the miR-15a/16-1 locus regardless of their cytogenetic profile. Interestingly, 15 out of 39 (∼39%) of all CLLs with T12, carry microdeletions of miR-15a/16-1, indicating that, in patients with T12, miR-15a/16-1 are mostly inactivated by microdeletions. In addition, ∼40% of CLL cases bearing T12, 17p−, and 11q− showed unidentified microdeletions of miR-15a/16-1, suggesting that miR-15a/16-1 loss cooperates with such chromosomal alterations in CLL. These data may have clinical relevance for the successful stratification of patients for treatment.

show abstract

The impact of trisomy 12, retinoblastoma gene and P53 in prognosis of B-cell chronic lymphocytic leukemia

Abstract: Interphase and metaphase FISH studies improve the cytogenetic diagnosis of chromosomal abnormalities in B-CLL. Lymphocytosis and trisomy 12 may be a good indicator of poor prognosis.

Cited by 6 publications

References 19 publications

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response

Development of plasma cell myeloma in a B-cell chronic lymphocytic leukemia patient with chromosome 12 trisomy

A large fraction of trisomy 12, 17p ⁻ , and 11q ⁻ CLL cases carry unidentified microdeletions of miR-15a/16-1

Contact Info

Product

Resources

About

The impact of trisomy 12, retinoblastoma gene and P53 in prognosis of B-cell chronic lymphocytic leukemia

Abstract: Interphase and metaphase FISH studies improve the cytogenetic diagnosis of chromosomal abnormalities in B-CLL. Lymphocytosis and trisomy 12 may be a good indicator of poor prognosis.

Cited by 6 publications

References 19 publications

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response

Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response

Development of plasma cell myeloma in a B-cell chronic lymphocytic leukemia patient with chromosome 12 trisomy

A large fraction of trisomy 12, 17p − , and 11q − CLL cases carry unidentified microdeletions of miR-15a/16-1

Contact Info

Product

Resources

About

A large fraction of trisomy 12, 17p ⁻ , and 11q ⁻ CLL cases carry unidentified microdeletions of miR-15a/16-1